Document is current

Article History

Received: 10 March 2021

Accepted: 19 January 2022

First Online: 3 February 2022

Declarations

:

: This is a retrospective chart review so informed consent was not required for data collection for this research study. However following local hospital processes, consent was obtained from patients by treating psychiatrists prior to clinical treatment in the TMS clinic. This study was conducted in accordance with the Declaration of Helsinki and was approved by the Research Ethics Board at the University of Western Ontario (project ID: 116274).

: All authors have consented for the publication on this report. Informed consent for publication of aggregate data from patients is not applicable given that this is a retrospective chart review study approved as such by Research Ethics Board at the University of Western Ontario (project ID: 116274).

: None for this work.

: LP reports personal fees from Janssen Canada, Otsuka Canada, SPMM Course Limited, UK, Canadian Psychiatric Association; book royalties from Oxford University Press; investigator-initiated educational grants from Janssen Canada, Sunovion and Otsuka Canada outside the submitted work. LP received travel support as a speaker for a meeting at Oxford, UK organized by Magstim limited in 2014. None related to this work.

: AMB reports personal fees from Janssen Canada, Avanir and Eisai pharmaceuticals for serving on advisory boards and from Atheneum Partners for providing expert consultation on market assessment. None are related to this work.